Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.
Install App?
Innovations in Pharmaceutical Technology (IPT)
www.iptonline.com
This is how the Install App dialog will look like once your App goes live.
rms Company Scales Medical Device Production with Addition of 3D Systems’ DMP Flex 350 Dual
- One of the largest US-based medical device manufacturers adds DMP Flex 350 Dual to its fleet of more than 30 3D Systems printers
- New 3D printer increasing productivity for rms’ powder to package capability, intended to open new applications for additive manufacturing
ROCK HILL, South Carolina, January 19, 2023 – Today, 3D Systems (NYSE:DDD) announced rms Company, one of the largest contract manufacturers of high-quality, tight-tolerance medical devices in the world, has added the DMP Flex 350 Dual to its production workflow. rms has more than 30 3D Systems’ DMP 3D printers in its additive manufacturing facility enabling the company to provide a complete Powder to Package capability to medical device OEMs. Powder to Package encompasses the entire manufacturing and post-processing workflow required to go from a digital file to a sterilized and packaged final product ready for the surgical suite. With the addition of the DMP Flex 350 Dual, rms believes they will be able to expand the types of implants they produce and accelerate throughput — helping to address the evolving application needs of the industry.
Over the course of four years, 3D Systems has helped rms expand its portfolio of direct metal printers from one machine to more than 30 — backed by a process that ensures repeatability across machines and supply chains — enabling true scaled production. As a result, rms has been able to cement its reputation for additively manufacturing high-quality titanium implants. With the addition of the DMP Flex 350 Dual which enables up to 50% productivity increases, rms will be able to increase throughput for smaller implants including those intended for spinal applications. They believe the same productivity increases will also open new opportunities in the production of large joint and extremity implants while allowing flexibility for existing projects.
“The increase in efficiency we get from the DMP Flex 350 Dual system creates new opportunities for larger and taller parts which were economically challenging with a single laser system,” said Ryan Kircher, senior additive manufacturing engineer, rms Company. “Another key reason rms Company decided to invest in a DMP Flex 350 Dual is that it is engineered in a way that allows us to produce the high precision, high-quality products we expect from our current installation of DMP systems without changing the processing parameters we validated when we initially developed our AM capabilities. This will allow us to explore not only new products but also reduce production times and costs on the products we are already making today.”
“The rms additive division owes a large part of our success to our customers,” said Troy Olson, director of operations – additive manufacturing division, rms Company. “Over the past several years, our customers have come to expect a continual flow of high-quality, additively manufactured medical devices. Our Powder to Package solution provides a complete end-to-end value proposition that allows us to control the entire manufacturing and packaging process flow. A key element of our process flow is the reliability and performance we get from our stable of 30-plus 3D Systems’ DMP ProX® 320 and DMP Flex 350 machines. Uptime on these machines is crucial for us to maintain our customer commitments. Our printers operate on a 24/7 production cadence, which leaves little room for downtime. 3D Systems has taken these first-in-class single laser platforms and have expanded on that technology with the DMP Flex 350 Dual. During our validation process, the DMP Flex 350 Dual showed no measurable differences in mechanical properties or dimensional accuracy. We are excited to add this new capability to our existing printing operation. As we continue to scale our additive manufacturing business, the 3D Systems DMP Flex 350 Dual will be at the forefront of our growth strategy.”
The DMP Flex 350 Dual is the most recent addition to 3D Systems’ Direct Metal Printing (DMP) portfolio. This dual-laser configuration maintains the benefits of the single-laser configuration including flexible application use and quick-swap build modules, and a central server to manage print jobs, materials, settings, and maintenance for 24/7 productivity. Additionally, the company’s unique vacuum chamber significantly reduces argon gas consumption while delivering best-in-class oxygen purity (<25 ppm). The printer also includes Oqton’s 3DXpert — the all-in-one software for industrial additive manufacturing that enables efficient preparation, optimization, lattice generation, and 3D printing of high-quality parts by streamlining the workflow from design to printing.
“Our Application Innovation Group worked alongside the rms team to develop, characterize and validate the DMP Flex 350 Dual as a seamless solution within their production environment,” said Jeph Ruppert, director, application innovation group, 3D Systems. “Our Direct Metal Printing (DMP) platform is recognized as an industry-leading technology for its ability to produce exceptionally high feature resolution parts of high chemical purity which makes it ideal for medical devices. Our collective application and technology expertise combined with the unparalleled capabilities of the DMP Flex 350 Dual is helping drive innovation for rms. They’ve established themselves as a world-class medical device manufacturer, and we are proud to be part of that journey.”
“Our collaboration with rms has spanned several years, and during that time rms has grown at a rate and scale that is truly impressive,” said Menno Ellis, executive vice president, healthcare solutions, 3D Systems. “They have not only delivered excellent solutions to the medical device community but have also grown their in-house additive knowledge, helping guide the industry to a more mature and robust position. Today, rms is expanding upon its capabilities and capacity with the addition of the DMP Flex 350 Dual. I look forward to seeing how this will enhance the breadth of applications they will be able to address for their customers, and the impact it will have for growth.”
About 3D Systems
More than 35 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading additive manufacturing solutions partner, we bring innovation, performance, and reliability to every interaction - empowering our customers to create products and business models never before possible. Thanks to our unique offering of hardware, software, materials, and services, each application-specific solution is powered by the expertise of our application engineers who collaborate with customers to transform how they deliver their products and services. 3D Systems’ solutions address a variety of advanced applications in healthcare and industrial markets such as medical and dental, aerospace & defence, automotive, and durable goods. More information on the company is available at www.3dsystems.com.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/d6d18ff8-39d3-4047-b805-cff46eed1dc6.png?optimizer=image&width=360&aspect_ratio=3:4)
bit.bio chooses Automata for automating an aspect of its production of iPSC derived human cells
26th January 2023, London UK – Automata, a leading robotics and automation company powering life sciences labs, today announced it is partnering with bit.bio, to automate a key aspect of the manufacturing process of their iPSC (induced pluripotent stem cell)-derived human cell products.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/7ce8f780-11bc-451e-b11e-aa0b6d632178.png?optimizer=image&width=360&aspect_ratio=3:4)
Thermo Fisher and AstraZeneca partner to Develop Solid Tissue, Blood-Based Companion Diagnostic Test
24 January -- CARLSBAD, Calif.--(BUSINESS WIRE)-- As part of a global, multiyear agreement, Thermo Fisher Scientific today announced it is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib).
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/1b83c600-5a94-4609-a117-c3cc2e65f43d.png?optimizer=image&width=360&aspect_ratio=3:4)
Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1
CARLSBAD, Calif.--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit, a Sanger sequencing-based assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that may resist common antiretroviral therapeutics.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/7016459e-99e9-4057-8f3a-9485bf0053fa.png?optimizer=image&width=360&aspect_ratio=3:4)
Ubiquigent and University of Glasgow to collaborate on drug discovery
Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neruodegenerative, renal, and cardiovascular diseases.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/371ef024-65a2-495e-afeb-0b98ffcd9e3a.png?optimizer=image&width=360&aspect_ratio=3:4)
InDevR raises $9 million in series B financing and partners with bioMérieux
Boulder, CO, 17th of January, 2023 – InDevR, Inc., a provider of best-in-class analytical technologies for vaccines and biotherapeutics, announced that it has raised $9 million in series B financing. Adjuvant Capital has invested $4 million, and bioMérieux – a worldwide leader in in vitro diagnostics and microbiological quality control solutions for the food and pharmaceutical industries – $5 million.
1
Human-Centred Design: From Inception to Integration
IPT sat down with Dr Chris Vincent at PDD, to understand more about the digital innovations that are leading design and whether technologies like Extended Reality (XR) can be beneficial to the process
2
The Importance of Temperature Control in Pharmaceutical Analysis
As technology within the analysis sphere continues to evolve, temperature control is becoming increasingly important for drug discovery and research
3
Providing Support Throughout the Patient Journey
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. How best can they be implemented?
